I would like to ask questions about medical inadmissibility related the cost of remicade.
I am applying for PR, however, the big cost (over 35000$/year) of remicade is a big issue. However, there is a slight chance here: the public drug plan (quebec) does not include remicade anymore. Instead, they only cover a cheaper biosimilar Infectra which costs around 18000-25000/year which falls in the threshold of the temporary medical inadmissibility act. However, there are exceptions for the remicade coverage: for example, RAMQ (quebec) says:
RemicadeTM remains payable to persons in the course of treatment who have received a refund from
Régie or an insurer or by the administrator of the benefits plan before February 15, 2017 and who
comply with the instructions giving right to payment.
In my case, I have been in the treatment since 2012 and never was using public drug plan. I was using the compassionate dose from the pharmaceutical company before Feb, 2017. My question is: Am I eligible for this exemption? I hope not, because then they will only cover the price of Infectra which is more hopeful to get approved from the medical officer.
My second question is: I applied my PR in the beginning of this year and the new temporary act about the new threshold (19900$) is effective in June. So, am I still eligible for this new threshold?
I know there are examples in this forum, some remicade users successfully defended their case, so I expect more helpful answers from you guys.
Big thanks!
I am applying for PR, however, the big cost (over 35000$/year) of remicade is a big issue. However, there is a slight chance here: the public drug plan (quebec) does not include remicade anymore. Instead, they only cover a cheaper biosimilar Infectra which costs around 18000-25000/year which falls in the threshold of the temporary medical inadmissibility act. However, there are exceptions for the remicade coverage: for example, RAMQ (quebec) says:
RemicadeTM remains payable to persons in the course of treatment who have received a refund from
Régie or an insurer or by the administrator of the benefits plan before February 15, 2017 and who
comply with the instructions giving right to payment.
In my case, I have been in the treatment since 2012 and never was using public drug plan. I was using the compassionate dose from the pharmaceutical company before Feb, 2017. My question is: Am I eligible for this exemption? I hope not, because then they will only cover the price of Infectra which is more hopeful to get approved from the medical officer.
My second question is: I applied my PR in the beginning of this year and the new temporary act about the new threshold (19900$) is effective in June. So, am I still eligible for this new threshold?
I know there are examples in this forum, some remicade users successfully defended their case, so I expect more helpful answers from you guys.
Big thanks!